PT - JOURNAL ARTICLE AU - Kelaiditis, Christos F. AU - Gibson, E. Leigh AU - Dyall, Simon C. TI - Effects of long-chain omega-3 polyunsaturated fatty acids on reducing anxiety and/or depression in adults; A systematic review and meta-analysis of randomised controlled trials AID - 10.1101/2022.10.17.22281092 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.17.22281092 4099 - http://medrxiv.org/content/early/2022/10/18/2022.10.17.22281092.1.short 4100 - http://medrxiv.org/content/early/2022/10/18/2022.10.17.22281092.1.full AB - First-line treatment for anxiety and depressive disorders comprises pharmacotherapy and psychotherapy; options not safe, effective, or suitable for all. Mounting evidence suggests that the omega-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic (EPA), docosahexaenoic (DHA) and docosapentaenoic (DPAn-3) acids are promising therapeutic options. However, meta-analyses of randomised controlled trials (RCTs) have produced inconsistent findings. This review assesses for the first time the efficacy of omega-3 PUFAs against the severity of anxiety and depression symptoms, measured by validated scales, with specific consideration of methodological issues encountered in this area. PubMed, CINAHL, PsycINFO, Cochrane Library and Web of Science were searched for eligible RCTs administering omega-3 PUFAs against anxiety and/or depression. This study adopts the PRISMA guidelines. Ten RCTs comprising 1509 participants were included in the quantitative synthesis. EPA-enriched interventions at ≥60% of total EPA+DHA were associated with significant reduction in depression severity, compared to placebo (SMD: −0.32; 95% CI: − 0.59, −0.06; p=0.02); however, EPA doses of ≥2000 mg/day were not (SMD: − 0.11; 95% CI: −0.43, 0.20; p=0.48). Only 10 RCTs fulfilled the eligibility criteria, and there were some concerns regarding bias and population heterogeneity, highlighting the lack of high-quality RCTs in this area. Overall, these results support previous observations where EPA at proportions ≥60% of total EPA+DHA, up to 2000 mg, reduces depression scores. However, more trials are needed which specifically consider the unique nature of this type of research to elucidate the therapeutic potential of EPA, DHA and DPAn-3.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a grant from Efamol Ltd who had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report and in the decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. https://www.crd.york.ac.uk/PROSPEROFILES/194402_STRATEGY_20201126.pdf